DV
Dividend Vision

MYGN — Myriad Genetics Inc

Myriad Genetics Inc (MYGN)

Total return is -34.7% over the past 30.9 years, 2199.0 points behind SPY at 2164.3%. Its deepest 1-year drawdown was 65.0%.

Myriad Genetics is a molecular diagnostics and precision medicine company that develops and offers DNA sequencing tests, tumor profiling tests, and pharmacogenomics tests across oncology, women's health, and mental health applications. The company does not currently distribute dividends. This stock appeals primarily to growth-oriented investors seeking exposure to the molecular diagnostics and personalized medicine sector.

MYGN key facts

Asset type
Stock
Asset class
Equity
Inception date
10/06/1995
Last close
$3.03
Market cap
$559,133,376
Average volume
1554800.0
Ex-dividend date
07/01/2009
Beta
1.637
Payout ratio
0.0
Forward P/E
54.0541
EPS
$-4.13